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Abstract
Background: Hepatitis B immune globulins (HBIG) in combination with nucleos(t)ide analogues (NA) are effectively 
used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, associated 
treatment costs for HBIG are exceedingly high.
Methods: Fresh frozen plasma obtained from blood donors with high anti-HBs levels (hyperimmune plasma, HIP) 
containing at least 4,500 IU anti-HBs was used as alternative treatment for HBV recurrence prophylaxis post-LT.
Results: Twenty-one HBV-related LT recipients received HIP starting at transplantation, followed by long-term 
combination treatment with NA. Mean follow-up time was 4.5 years (range 0.5-12.6) and each patient received on 
average 8.2 HIP per year (range 5.8-11.4). Anti-HBs terminal elimination kinetic after HIP administration was 20.6 days 
(range 13.8-30.9), which is comparable to values reported for commercial HBIG products. All 21 patients remained free 
of HBV recurrence during follow-up and no transfusion-transmitted infection or other serious complication was 
observed. Seven patients developed reversible mild transfusion reactions. The cost for one HIP unit was US$140; 
average yearly HBIG treatment cost was US$1,148 per patient, as compared to US$25,000-100,000 for treatment with 
commercial HBIG.
Conclusion: The results of this study suggest that the use of HIP may be a useful and economical approach for the 
prevention of HBV recurrence post-LT if used in combination with NA. Additional prospective controlled studies in 
larger populations are needed to confirm these results.
Background
Without prophylactic treatment up to 80% of HBV-
related liver transplantation (LT) recipients develop
recurrent HBV infection after LT leading to graft damage,
organ failure and increased morbidity and mortality [1-
4]. Passive immunoprophylaxis with hepatitis B immune
globulins (HBIG) in combination with nucleos(t)ide ana-
logues (NA), such as lamivudine or adefovir, is highly
effective for the prevention of HBV reinfection with
reported HBV recurrence in only 0-10% of patients dur-
ing long-term follow up after LT [5-7].
However, the costs of HBV reinfection prophylaxis with
intravenous HBIG are extremely high and economic
aspects become an important issue in the long-term care
of these patients. The estimated cost for commercial
intravenous HBIG in the peri-transplantation period
range from US$50,000 to $80,000, followed by US$25,000
to $100,000 per year during long-term treatment thereaf-
ter [8-11]. Thus, over recent years efforts have been made
to search for less costly regimens such as limiting HBIG
treatment to 18-24 months after LT and thereafter life-
long NA therapy either in mono- or bi-therapy [12-15]; or
low-dose intramuscular HBIG in association with NA
[16-18]. Furthermore, recent studies suggest that patients
can be stratified in high and low risk for HBV recurrence
based on the levels of HBV DNA prior to LT [9]. High-
risk patients for HBV recurrence present detectable
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HBV-DNA levels at LT and might profit from high-dose
long-term administration of HBIG combined with NA as
earlier studies showed [10,19,20]. However, in the
absence of clear data showing which patients could be
suspended from HBIG, long-term HBIG therapy remains
the standard of care in many centers [2].
In search of an alternative approach that would reduce
costs but maintain maximum efficacy to protect from
HBV recurrence, we used substituted commercial HBIG
formulations fresh frozen plasma (FFP) with high anti-
HBs titers (hyperimmune plasma = HIP). HIP can be eas-
ily produced in any blood transfusion center and our
experience provides data on long-term efficacy, kinetics,
safety and economics of HIP for the prevention of HBV
reinfection after LT.
Methods
Patients, hyperimmune plasma administration and follow-
up
In this study we report our long-term experience with 21
patients with HBV-related end-stage liver disease (ESLD)
who received HIP for prevention of HBV reinfection after
LT. Patients underwent liver transplantation at the
Geneva University Hospital between 1989 and 2007 for
HBV-related cirrhosis (n = 16), fulminant HBV (n = 3)
and cirrhosis from HBV-HDV infection (n = 2) and were
subsequently followed at two hepatology outpatient clin-
ics (Geneva and Lugano) (Table 1). All patients except
two were serum HBV-DNA negative at the time of trans-
plantation. The two with detectable HBV DNA prior LT
were transplanted 1989 and 1993 respectively (the HBV
status of all patients is summarized in Table 1). Before
1996, patients received only HIP as recurrence prophy-
laxis because NA were unavailable at this time. Since
1996, combination therapy with HIP and NA (Lamivu-
dine, 100 mg daily or Adefovir, 10 mg daily) was standard
treatment for all patients. Two patients died during fol-
low-up from non HBV-related causes. All patients except
the three patients with fulminant HBV infection had
chronic hepatitis B infection with HBsAg and anti-HBc
for at least 6 months before evaluation for liver transplan-
tation. With the exception of the first two patients (H1,
H2), all patients with positive HBV DNA at LT evaluation
were started on NA and treated while being on the wait-
ing list in order to achieve undetectable HBV DNA at the
moment of transplantation. The three patients with ful-
minant HBV infection were not previously known for
chronic HBV infection and not vaccinated against HBV,
but had a clear exposure to HBV and their serological sta-
tus at time of diagnosis indicated a recent infection. All
three cases however had undetectable HBV DNA at LT.
The serological status of all patients before LT is summa-
rized in Table 1.
All patients received intra-operatively, during the anhe-
patic phase, at least two HIP units (range 2-10 units),
each containing at least 4,500 IU anti-HBs antibodies.
Postoperatively, patients received one HIP unit per day
for 7 days, and then once weekly for 3 weeks post-LT.
Anti-HBs serum antibody levels were measured every 4
to 8 weeks thereafter and patients received HIP on
demand to maintain anti-HBs levels above 200 IU/L.
HIP was administered intravenously over a period of 1
to 3 hours in a volume of 300 ml (± 20 ml) without any
pre-medication. During the transfusion all patients were
closely observed, and blood pressure, pulse and body
temperatures were measured twice an hour. If any allergic
reaction appeared, HIP transfusions were stopped and
substituted with 5,000 IU commercial HBIG. Efficacy was
determined by testing the anti-HBs titer every 4-8 weeks
and HBsAg and HBV DNA twice per year. Occasionally
no HIP was available at the blood bank, in which case
patients received 5,000 IU commercial HBIG.
The study was approved by the local Ethics Committees
(in Geneva and Lugano) and the Swiss Agency for Thera-
peutic Products (Swissmedic protocol 2006DR2070).
Hyperimmune plasma production, quarantine and stability
Fresh frozen plasma (FFP) derived from donors with high
anti-HBs titers (>15,000 IU/L) was obtained either from
whole blood donations or with plasmapheresis. Initially
methylene blue for virus inactivation was added to the
FFP but was discontinued in 1998 in favor of product
quarantine (see below). All donors met the national crite-
ria for blood donation (Swiss Red Cross Blood Donation
Service, SRCBDS). Plasmapheresis was performed with a
Haemonetics PCS2 device. From each apheresis proce-
dure, two units of 300 ml (± 20 ml) filtered, leukocyte-
deprived plasma (leuco-depletion 95%, <1 × 106 leuco-
cytes, according to the manufacturer) were collected.
Each HIP unit contained therefore at least 4,500 IU anti-
HBs antibodies. All donated plasma products were
screened for serological markers according to the
SRCBDS guidelines including determination of anti-HCV
(test introduced 1990), HCV RNA (1999), HBsAg (1974),
HBV DNA (2007), anti-HIV (1985), HIV RNA (2002),
Treponema pallidum (1974) and ALT levels (1989). The
plasma was shock-frozen with a process that allows com-
plete freezing within one hour to a core temperature
below -30°C. After freezing, each plasma unit was stored
at -80°C for at least four months but not more than 24
months for quarantine when donors were tested again for
the presence of serological markers. After the second
negative serological testing the HIP product was released
from the blood bank for intravenous transfusion.
Some donors had persistently very high serum anti-
HBs levels (>25,000 IU/L) but in others, levels dropped
below the desired concentration and those received aB
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Table 1: Demographic data and serological and treatment status of all patients before liver transplantation
Patient Gender Age at LT Ethnicity Year of LT HBeAg anti-HBe anti-HBc HBV DNA at LT NA before LT Cause for LT
H1 M 42 caucasian 1989 NA NA positive qual. positive, quant. NA none Cirrhosis
H2 M 53 caucasian 1993 negative positive positive 270 pg/ml none Cirrhosis
H3 F 41 caucasian 1996 positive positive negative undetectable none Fulminant HBV
H4 M 45 caucasian 1996 negative negative positive undetectable Lamivudine Cirrhosis
H5 M 59 caucasian 1996 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H6 M 33 caucasian 1996 positive negative positive undetectable Lamivudine Cirrhosis + HDV
H7 M 60 caucasian 1997 positive negative positive undetectable Lamivudine Cirrhosis + HDV
H8 M 48 caucasian 1997 negative negative positive undetectable Lamivudine Cirrhosis
H9 M 53 Hispanic 2000 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H10 M 48 caucasian 2000 negative negative positive undetectable Lamivudine Cirrhosis
H11 F 43 caucasian 2000 positive negative negative undetectable none Fulminant HBV
H12 M 63 caucasian 2001 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H13 F 54 caucasian 2001 negative negative positive undetectable Lamivudine Cirrhosis
H14 M 60 caucasian 2002 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H15 M 58 caucasian 2002 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H16 M 60 caucasian 2002 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H17 M 60 caucasian 2003 negative negative positive undetectable Lamivudine Cirrhosis + HCC
H18 M 48 caucasian 2004 negative negative positive undetectable Lamivudine Cirrhosis
H19 M 51 caucasian 2005 positive positive negative undetectable none Fulminant HBV
H20 F 30 african 2007 positive negative positive undetectable Adefovir+Lamivudine Cirrhosis
H21 M 49 african 2007 positive negative positive undetectable Adefovir+Lamivudine Cirrhosis + HCCBihl et al. BMC Gastroenterology 2010, 10:71
http://www.biomedcentral.com/1471-230X/10/71
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HBV booster vaccination (Engerix-B20, GlaxoSmith-
Kline, Belgium). Production costs for one HIP unit were
estimated as US$140 (150 CHF), including the sterile sin-
gle-use kit for plasmapheresis (MCS+9000 system; Hae-
monetics, Switzerland), two serology tests, storage costs
for quarantine, screening for anti-HBs level in volunteer
donors, booster vaccination and personnel expenses for
donor randomization.
Quality control and sample collections for elimination 
kinetics of anti-HBs after HIP administration
To evaluate whether plasmapheresis and/or storage at -
80°C for 4-24 months would lead to a decrease of anti-
HBs concentrations, we determined anti-HBs levels in 15
HIP units at the time of donation (in the plasma) and
again at the time of transfusion (after freezing for 4-24
months for quarantine and thawing to room temperature
before transfusion).
In order to determine the elimination kinetics of anti-
HBs during long-term treatment with HIP, we measured
anti-HBs plasma levels just before the HIP transfusion,
directly after end of transfusion, and then 1 and 24 hours,
and 3, 10, 14, 21 and 30 days after transfusion in 5
patients (H2, H4, H7, H15, H17). All patients were on
long-term treatment with HIP and at least 4 years after
LT (range 4-14 years).
Analytical methods
Anti-HBs were determined using an enzyme immunoas-
say (AUSAB) with an Abbott AxSYM device (Abbott Lab-
oratories, IL, USA). Quantitative serum HBV DNA was
measured with a commercial real-time PCR kit (Taqman,
Roche, Switzerland introduced 2006. Prior to 2006 a
Roche Cobas Amplicore assay was used).
Data analysis
A paired t-test was used for the comparison of anti-HBs
concentrations measured at the time of donation and
again at transfusion.
Calculation of anti-HBs plasma half-life after HIP
transfusion was carried out by first visually controlling
individual patient data in order to select only data points
representing the terminal elimination phase. Anti-HBs
half-life (t1/2) was subsequently calculated from the last 5
data points in all patients. We assumed linear kinetics, i.e.
the elimination constant (k) was calculated as the slope of
a linear regression line through these data points after
logarithmic transformation of anti-HBs concentrations.
Terminal elimination half-life was then calculated as t1/2 =
ln2/k.
Data analyses and graphs were done using STATA ver-
sion 8.2 for MacOS X (STATA Corp., College Station, TX,
USA).
Results
Safety
Seven patients developed hypersensitivity reactions dur-
ing HIP transfusions, such as hot flushes or an itching
skin rash, which were treated with 2 mg clemastine iv.
HIP transfusions were discontinued in these patients and
they were switched for some months to commercial
HBIG preparations (Hepatect®CP, Biotest, Dreieich, Ger-
many). Later they were treated with HIP again but with a
pre-medication of clemastine (1 mg po) two hours before
transfusion, which resulted in good tolerance in all
patients. These events were reported as transfusion reac-
tions to the regional hemovigilance system. We observed
no major transfusion reactions such as anaphylactic reac-
tions or transfusion-related acute lung injury (TRALI),
and no transfusion-transmitted infectious diseases.
HIP transfusions, anti-HBs levels and efficacy
Information on follow-up, HIP administrations and anti-
HBs determinations are presented in Table 2. Mean fol-
low-up time with HIP transfusion treatment was 4.5
years (range 0.5 to 12.6 years), and the cumulative follow-
up time for all 21 patients was 95.1 years. The average
number of HIP transfusions was 8.2 per year (range 5.8-
11.4), which corresponds to one HIP transfusion every 6-
7 weeks.
Median anti-HBs levels, pooled from all 21 patients,
during HIP treatment were 507 IU/L. Of note, these val-
ues were mostly determined shortly before the next
transfusion and therefore represent trough levels rather
than average concentrations during HIP treatment.
Regarding the level of protection against HBV recur-
rence, the proportion of values below a certain lower
limit such as 200 or 100 IU/L may be of interest, and is
therefore presented in Table 2 and Figure 1.
Pooled anti-HBs levels during HIP treatment from all
21 patients are summarized in a histogram (Figure 1)
showing their relative distribution in comparison to anti-
HBs levels during treatment with commercial HBIG in
eight patients who switched treatment temporarily (7
patients switched momentarily for intolerance and one
patient switched for logistic reasons, see next paragraph)
The proportion of measured anti-HBs values <200 IU/L
and <100 IU/L during treatment with commercial HBIG
was 17.2% and 7.0%, respectively, compared to 13.2% and
2.3% during HIP treatment. As reported for other HBIG
formulations, we observed a pronounced inter- and intra-
individual variability in anti-HBs titers under HIP treat-
ment. And finally, all patients remained free of HBV
recurrence during follow-up as indicated by negative
HBsAg and HBV DNA determinations.
Figure 2 shows anti-HBs levels and HBIG administra-
tion in one representative patient (H4), who was followed
for 11.4 years after LT: this patient moved temporarilyB
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Table 2: Follow-up time and anti-HBs levels during HIP treatment
Patient Follow-up with 
HIP (years)
HIP transfusions (n) HIP transfusions per 
year (mean)
HIP costs per 
year (USD)
Anti-HBs 
determinations (n)
Anti-HBs (IU/L) 
median (range)
Anti-HBs <200 
IU/L n (%)
Anti-HBs <100 
IU/L n (%)
H1 12.6 137 10.8 1512 134 259 (38-8578) 46 (34.3) 11 (8.2)
H2 10.5 86 8.2 1148 86 351 (84-17567) 21 (24.4) 3 (3.5)
H3 5.2 34 6.5 910 51 324 (108-3555) 9 (17.6) 0 (0)
H4 9.4 65 6.9 966 82 393 (116-2130) 10 (12.2) 0 (0)
H5 11.1 125 11.2 1568 133 711 (191-3911) 1 (0.8) 0 (0)
H6 5.0 35 7.0 980 37 518 (166-1798) 3 (8.1) 0 (0)
H7 8.7 69 7.9 1106 71 454 (107-1123) 8 (11.3) 0 (0)
H8 0.5 4 8.3 1162 7 188 (76-578) 4 (57.1) 1 (14.3)
H9 1.3 10 7.8 1092 12 508 (69-1050) 1 (8.3) 1 (8.3)
H10 0.9 8 9.4 1316 21 623 (273-3016) 0 (0) 0 (0)
H11 7.2 42 5.8 812 49 560 (217-1275) 0 (0) 0 (0)
H12 2.8 21 7.5 1050 39 512 (166-2976) 3 (7.7) 0 (0)
H13 6.1 41 6.7 938 50 884.5 (101-3266) 1 (2) 0 (0)
H14 2.1 15 7.2 1008 28 829.5 (191-5048) 2 (7.1) 0 (0)
H15 1.4 10 7.2 1008 21 609 (225-2728) 0 (0) 0 (0)
H16 0.5 4 7.8 1092 7 1939 (156-5558) 1 (14.3) 0 (0)
H17 4.9 33 6.8 952 26 445.5 (95-3792) 7 (26.9) 1 (3.8)
H18 1.1 10 9.5 1330 21 597 (14-2489) 3 (14.3) 2 (9.5)
H19 2.3 16 7.1 994 30 512.5 (49-4525) 2 (6.7) 1 (3.3)
H20 0.6 7 10.8 1512 12 775.5 (63-1000) 2 (16.7) 1 (8.3)
H21 0.9 10 11.4 1596 16 721.5 (208-1000) 0 (0) 0 (0)
All patients 95.1 782 8.2 1148 933 507 (14-17567) 124 (13.2) 21 (2.3)Bihl et al. BMC Gastroenterology 2010, 10:71
http://www.biomedcentral.com/1471-230X/10/71
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Figure 1 Anti-HBs levels during treatment with HIP versus commercial HBIG. Pooled anti-HBs levels from all 21 patients during treatment with 
HIP and anti-HBs levels in 8 patients when they were switched to commercial HBIG
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Figure 2 Transfusions and anti-HBs levels in one patient who was temporarily switched to commercial HBIG and then back to HIP. Between 
October 1998 and September 2000 this patient received commercial HBIG due to logistic reasons (lived temporarily far away from a transfusion center 
providing HIP).
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from the transfusion center providing HIP and received
commercial HBIG for two years (5000 IU at each transfu-
sion). During this time he needed 10 HBIG administra-
tions per year, compared to an average of 6.9 HIP
transfusions per year during HIP treatment. The median
anti-HBs levels during HIP treatment and commercial
HBIG were 393 IU/L (range 116 to 2130) and 144 IU/L
(range 63 to 494), respectively. The proportion of anti-
HBs values <200 IU/L and <100 IU/L during treatment
with commercial HBIG were 73.7% and 31.6%, respec-
tively, compared to 12.2% and 0%, during HIP treatment.
In conclusion, annual treatment costs in this patient were
considerably higher during commercial HBIG treatment
(US$39,579 versus US$966 during HIP treatment) and
HIP transfusions resulted in higher anti-HBs levels com-
pared to commercial HBIG treatment (Figure 2).
Kinetics of anti-HBs elimination
Five patients participated in the study of anti-HBs kinet-
ics. Anti-HBs plasma levels directly before and after HIP
transfusions are presented in Figure 3. Mean terminal
elimination half-life of anti-HBs was 20.6 days with pro-
nounced interindividual variability (range 13.8 to 30.9
days).
Stability of anti-HBs levels in HIP
Anti-HBs concentrations measured in 15 HIP units at the
time of donation and again at transfusion are presented in
Figure 4. As shown, anti-HBs concentrations decreased in
all but one sample between donation and transfusion.
The mean relative concentration at the time of transfu-
sion was 72.4% compared to the concentration at the time
of donation (p < 0.001). Absolute anti-HBs concentra-
tions were above 6,000 IU/L in all 15 tested samples with
Figure 3 Kinetics of anti-HBs after HIP transfusion. Kinetics of anti-
HBs levels after transfusion of one HIP unit in 5 patients during long-
term HIP treatment.
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a mean of 15,959 IU/L at the time of transfusion. There
was no correlation between either absolute or relative
changes in anti-HBs concentrations and storage time
(data not shown).
Cost analysis
The price of one HIP unit was US$140 corresponding to
the price of one fresh frozen plasma unit in Switzerland.
In our experience, the average annual HBIG treatment
cost per patient was US$1,148, ranking from US$812 to
U$1,596 (Table 2). Thus, HIP treatment costs were nota-
bly lower than reported annual treatment costs with
commercial HBIG formulations ranking between
US$25,000 and $100,000 [11,21,22]. Interestingly, the HIP
treatment cost was even lower than the annual cost of
Lamivudine (US$2,396) or Adefovir (US$12,223) in Swit-
zerland. Furthermore, at the time of donation, mean anti-
HBs concentrations were 15,959 IU/L, or expressed as the
absolute value 4,788 IU per transfused unit, which corre-
sponds to a price of US$15 per 500 IU. This value com-
pares to the 23-times-higher price of US$345 (370 CHF)
for 500 IU commercial HBIG (Hepatect®) in Switzerland.
Discussion
The introduction of treatment with HBIG was a major
breakthrough for the prevention of HBV recurrence after
HBV-related LT. Although there is no clear consensus on
the optimal HBIG dosage and duration, it is widely
accepted that HBIG plasma titers should not fall below
100 IU/L during long-term therapy. Even though earlier
studies showed that higher anti-HBs levels (300-500 IU/
L) seem to confer better protection against HBV recur-
rence, [20,23] the exceedingly high costs of commercial
HBIG formulations force clinicians to search for alterna-
tives in order to lower long-term expenses in HBV-
related LT recipients. Attempts to reduce the expenses
for HBIG treatment in the past include lower HBIG
doses, HBIG administration by the intramuscular rather
than the intravenous route, or tailored HBIG administra-
tion guided by plasma concentrations rather according to
a fixed time schedule [2]. Furthermore, a recent study
analyzed the long-term risk of HBV recurrence after
HBIG discontinuation but continued NA therapy and
found an HBV recurrence risk of 9% at 4 years after HBIG
discontinuation (12). All these approaches appear to
lower costs at the price of increasing the risk of HBV
recurrence with consequent graft damage. In the search
for new approaches with lower costs and maximum effi-
cacy HIP has been used in some centers but previous
reports included only a limited follow-up time with this
approach [24,25].
This preliminary long-term experience shows that HIP
treatment can achieve anti-HBs levels that are compara-
ble to or even higher than those seen under administra-
tion of commercial HBIG. In particular, only 2.7% of
measured anti-HBs levels were below 100 IU/L and HBV
recurrence could be prevented in all 21 patients with an
average follow-up time of 4.5 years. In addition to this
convincing efficacy, patients required on average only
one transfusion every 6 to 7 weeks, which is convenient
and may help to maintain treatment compliance. Above
all, HIP treatment achieved the important goal of sub-
stantially reducing the exceedingly high costs associated
with commercial HBIG formulations. An additional
advantage is that HIP can be easily produced in any blood
transfusion center, where its production does not require
special approval because HIP is made as FFP and there-
fore subject to the rigorous national safety standards that
regulate blood transfusion and assure the safety of blood
products. Nevertheless we realize that HIP, being a blood
product, carries a residual risk for transmission of blood-
borne pathogens for which donors are not screened (e.g.
HEV). However, it is worth noting that in principle this
also applies to commercial HBIG formulations, which
likewise are human-derived blood products. The quaran-
tine storage and repeated donor screening decrease the
risk of infection with screened-for pathogens and provide
the benefit of virtually no side effects, such as toxicity
described for methylene blue [26]. In contrast, pathogen
inactivation approaches including methylene blue or sol-
vent detergent treatment, used for the production of
commercial HBIG formulations, might be deficient for
inactivation of some non-enveloped pathogens (e.g.
HEV) [27]. However, in our long-term experience with a
cumulative follow-up time of 95 years in 21 patients we
did not detect any HIP-related blood-borne diseases. And
finally, one should also consider that a high number of
blood components are usually transfused during LT.
Another safety issue with HIP treatment are transfu-
sion reactions. In our series, seven patients, i.e. 33% pre-
sented at least one transfusion-related side effect such as
hot flushes or itching skin rash during long term HIP
treatment. However, all reactions were mild and could be
managed with antihistamines; premedication with clem-
astine allowed the safe use of HIP in all patients. Thus we
recommend premedication for all patients who present at
least one allergic reaction. We observed pronounced
inter- as well as intra-individual variability in anti-HBs
titers under HIP treatment, which apparently related to
variability in anti-HBs concentrations in the administered
HIP units. Nevertheless, the pragmatic approach of
administering HIP followed by close monitoring of anti-
HBs plasma concentrations but without determination of
anti-HBs concentrations in the transfused units has the
advantage of simple logistics and can be justified consid-
ering high anti-HBs levels that were achieved in all
patients after transfusion of HIP leading to efficacious
prevention of HBV recurrence. Besides, considerableBihl et al. BMC Gastroenterology 2010, 10:71
http://www.biomedcentral.com/1471-230X/10/71
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variability in anti-HBs kinetics has also been described
after administration of commercial HBIG formulations
[11,21,28]. The calculated terminal anti-HBs half-life of
20.6 days as well as the observed variability is closely sim-
i l a r  t o  w h a t  h a s  b e e n  r e p o r t e d  a f t e r  a d m i n i s t r a t i o n  o f
commercial HBIG formulations [28]. Finally, another
benefit of HIP is that it can be used as FFP during the LT
procedure, and in this way very high anti-HBs levels can
be achieved during the entire operative phase without
excessive costs.
On the other hand, long-term intravenous HBIG treat-
ment may be tedious and new approaches such as low
dose i.m. HBIG administration or even HBIG discontinu-
ation are now also considered as possible alternatives.
However, the administration of HIP could still be a valu-
able treatment for the initial intraoperative phase and the
first weeks post-LT, followed by a switch to other HBIG
regimens such as low dose i.m. later on.
Conclusion
In summary, the presented results indicate that HIP in
combination with an oral antiviral drug may be a valid
and safe option for prophylaxis of HBV recurrence after
LT. Local HIP production is an easy procedure that can
be done with routine procedures at any blood transfusion
center and HIP administration can dramatically reduce
the exceedingly high costs associated with commercial
HBIG formulations after HBV-related LT. Because of the
limited number of patients in this study further studies
are required in order to establish the validity of this
approach.
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